Examining the European Pharma legislation: EFPIA publishes the Dolon Report
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has commissioned Dolon to develop a report to assess the impact of the proposed European Commission pharma legislation. The Dolon Report, published on 6 November, has projected that the proposed legislation will negatively impact research and development in the pharmaceutical industry in Europe, potentially impacting the lives of patients around the world. Below are some of the projected outcomes if the legislation is adopted.
Find out more about the potential impact: read EFPIA’s press release here and the full report here.
H1 Results: a strong first half of 2025
H1 2025 Results
Q1 2025 sales update
Financial results for the first nine months of 2024
Financial results for the first half of 2024
Our 2023 Integrated Annual Report is live!
Q1 2024 sales update
Applications now open for the 2024 Golden Ticket competition
FY 2023 results announcement
Ipsen sponsors 5 elite athletes on their journeys to the 2024 Paralympics